Impairment of hepatic growth hormone and glucocorticoid receptor signaling causes steatosis and hepatocellular carcinoma in mice

Growth hormone (GH)‐activated signal transducer and activator of transcription 5 (STAT5) and the glucocorticoid (GC)‐responsive glucocorticoid receptor (GR) are important signal integrators in the liver during metabolic and physiologic stress. Their deregulation has been implicated in the developmen...

Full description

Saved in:
Bibliographic Details
Published inHepatology (Baltimore, Md.) Vol. 54; no. 4; pp. 1398 - 1409
Main Authors Mueller, Kristina M., Kornfeld, Jan‐Wilhelm, Friedbichler, Katrin, Blaas, Leander, Egger, Gerda, Esterbauer, Harald, Hasselblatt, Peter, Schlederer, Michaela, Haindl, Susanne, Wagner, Kay‐Uwe, Engblom, David, Haemmerle, Guenter, Kratky, Dagmar, Sexl, Veronika, Kenner, Lukas, Kozlov, Andrey V., Terracciano, Luigi, Zechner, Rudolf, Schuetz, Guenther, Casanova, Emilio, Pospisilik, J. Andrew, Heim, Markus H., Moriggl, Richard
Format Journal Article
LanguageEnglish
Published Hoboken Wiley Subscription Services, Inc., A Wiley Company 01.10.2011
Wiley
Wiley Subscription Services, Inc
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Growth hormone (GH)‐activated signal transducer and activator of transcription 5 (STAT5) and the glucocorticoid (GC)‐responsive glucocorticoid receptor (GR) are important signal integrators in the liver during metabolic and physiologic stress. Their deregulation has been implicated in the development of metabolic liver diseases, such as steatosis and progression to fibrosis. Using liver‐specific STAT5 and GR knockout mice, we addressed their role in metabolism and liver cancer onset. STAT5 single and STAT5/GR double mutants developed steatosis, but only double‐mutant mice progressed to liver cancer. Mechanistically, STAT5 deficiency led to the up‐regulation of prolipogenic sterol regulatory element binding protein 1 (SREBP‐1) and peroxisome proliferator activated receptor gamma (PPAR‐γ) signaling. Combined loss of STAT5/GR resulted in GH resistance and hypercortisolism. The combination of both induced expression of adipose tissue lipases, adipose tissue lipid mobilization, and lipid flux to the liver, thereby aggravating STAT5‐dependent steatosis. The metabolic dysfunctions in STAT5/GR compound knockout animals led to the development of hepatic dysplasia at 9 months of age. At 12 months, 35% of STAT5/GR‐deficient livers harbored dysplastic nodules and ∼60% hepatocellular carcinomas (HCCs). HCC development was associated with GH and insulin resistance, enhanced tumor necrosis factor alpha (TNF‐α) expression, high reactive oxygen species levels, and augmented liver and DNA damage parameters. Moreover, activation of the c‐Jun N‐terminal kinase 1 (JNK1) and STAT3 was prominent. Conclusion: Hepatic STAT5/GR signaling is crucial for the maintenance of systemic lipid homeostasis. Impairment of both signaling cascades causes severe metabolic liver disease and promotes spontaneous hepatic tumorigenesis. (HEPATOLOGY 2011;54:1398–1409)
Bibliography:These authors contributed equally to this work.
This work was supported by grant SFB F28 from the Austrian Science Funds (FWF; to R.M., J.W.K., K.M.M., V.S., and K.F.) and grant SFB F30 (FWF; to G.H., D.K., and R.Z.). G.E. was supported by an Elise Richter fellowship (FWF; V102‐B12). L.B. and E.C. were supported by grant GEN‐AU Austromouse. H.E. and J.A.P. were supported by grants of the Vienna Science and Technology Fund (WWTF project LS07‐058) and JDRF.
Re‐use of this article is permitted in accordance with the Terms and Conditions set out at
Potential conflict of interest: Nothing to report.
http://wileyonlinelibrary.com/onlineopen#OnlineOpen_Terms
fax: (43)‐14277‐9641
ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
Additional Supporting Information may be found in the online version of this article.
View this article online at wileyonlinelibrary.com.
This work was supported by grant SFB F28 from the Austrian Science Funds (FWF; to R.M., J.W.K., K.M.M., V.S., and K.F.) and grant SFB F30 (FWF; to G.H., D.K., and R.Z.). G.E. was supported by an Elise Richter fellowship (FWF; V102-B12). L.B. and E.C. were supported by grant GEN-AU Austromouse. H.E. and J.A.P. were supported by grants of the Vienna Science and Technology Fund (WWTF project LS07-058) and JDRF.
Address reprint requests to: Richard Moriggl, Ph.D., Ludwig-Boltzmann-Institute for Cancer Research, Waehringerstrasse 13a, A-1090 Vienna, Austria. E-mail: richard.moriggl@lbicr.lbg.ac.at; fax: (43)-14277-9641.
ISSN:0270-9139
1527-3350
1527-3350
DOI:10.1002/hep.24509